Leerink Partnrs Has Negative Estimate for Humana Q4 Earnings

Humana Inc. (NYSE:HUM) – Investment analysts at Leerink Partnrs decreased their Q4 2024 earnings per share (EPS) estimates for shares of Humana in a report issued on Wednesday, October 30th. Leerink Partnrs analyst W. Mayo now expects that the insurance provider will post earnings per share of ($2.16) for the quarter, down from their previous forecast of ($1.57). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $16.10 per share. Leerink Partnrs also issued estimates for Humana’s Q1 2025 earnings at $6.91 EPS, Q2 2025 earnings at $7.08 EPS, Q3 2025 earnings at $3.68 EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at $16.86 EPS, FY2026 earnings at $16.09 EPS and FY2027 earnings at $28.36 EPS.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion.

Several other analysts have also weighed in on HUM. Barclays raised their price objective on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research note on Thursday. UBS Group reduced their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. Royal Bank of Canada reduced their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Finally, TD Cowen lowered Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $402.00 to $261.00 in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $315.48.

Humana Stock Up 1.1 %

Shares of NYSE HUM opened at $260.71 on Monday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.66 and a current ratio of 1.76. Humana has a 52 week low of $213.31 and a 52 week high of $527.18. The stock has a market capitalization of $31.39 billion, a P/E ratio of 23.09, a PEG ratio of 2.00 and a beta of 0.52. The stock’s fifty day moving average is $297.06 and its 200 day moving average is $334.52.

Institutional Investors Weigh In On Humana

Several hedge funds and other institutional investors have recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. grew its holdings in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares in the last quarter. Creative Financial Designs Inc. ADV grew its holdings in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares in the last quarter. Atwood & Palmer Inc. bought a new stake in Humana during the third quarter worth $29,000. Hantz Financial Services Inc. bought a new stake in Humana during the second quarter worth $35,000. Finally, Family Firm Inc. bought a new stake in Humana during the second quarter worth $37,000. Institutional investors own 92.38% of the company’s stock.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.36%. Humana’s payout ratio is currently 31.36%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.